A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589 · Asthma
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
PhasePhase 3
TypeInterventional
Age5 Years – 11 Years
WhereMontgomery, Alabama, United States + 146 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts
147 sitesApply